Sei Naito

2.1k total citations
101 papers, 1.4k citations indexed

About

Sei Naito is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Sei Naito has authored 101 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 34 papers in Molecular Biology and 31 papers in Cancer Research. Recurrent topics in Sei Naito's work include Renal cell carcinoma treatment (48 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (21 papers). Sei Naito is often cited by papers focused on Renal cell carcinoma treatment (48 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (21 papers). Sei Naito collaborates with scholars based in Japan, United States and South Korea. Sei Naito's co-authors include Yoshihiko Tomita, Hideyuki Akaza, Tomoyuki Kato, Vladimir Bilim, Tadashi Tsukamoto, Kaori Yuuki, Akira Nagaoka, Masaru Murai, Norihiko Tsuchiya and K. Nakajima and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Sei Naito

92 papers receiving 1.4k citations

Peers

Sei Naito
Nils Kroeger United States
Hilary Glen United Kingdom
Dale R. Shepard United States
Anusha Vakiti United States
Nils Kroeger United States
Sei Naito
Citations per year, relative to Sei Naito Sei Naito (= 1×) peers Nils Kroeger

Countries citing papers authored by Sei Naito

Since Specialization
Citations

This map shows the geographic impact of Sei Naito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sei Naito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sei Naito more than expected).

Fields of papers citing papers by Sei Naito

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sei Naito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sei Naito. The network helps show where Sei Naito may publish in the future.

Co-authorship network of co-authors of Sei Naito

This figure shows the co-authorship network connecting the top 25 collaborators of Sei Naito. A scholar is included among the top collaborators of Sei Naito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sei Naito. Sei Naito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sazuka, Tomokazu, Katsunori Tatsugami, Suguru Shirotake, et al.. (2025). Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study. International Journal of Urology. 33(1). e70281–e70281.
2.
Sakurada, Kaori, Sei Naito, Atsushi Yamagishi, et al.. (2025). Association Between Overactive Bladder and Sarcopenia in Older Adults: A Population‐Based Cohort Study. International Journal of Urology. 32(8). 1016–1022.
4.
Naito, Sei, Takahiro Osawa, Kazuyuki Numakura, et al.. (2025). Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations. BMC Cancer. 25(1). 117–117. 1 indexed citations
5.
Naito, Sei, et al.. (2024). Urinary continence outcomes after robot‐assisted laparoscopic radical prostatectomy: Significance of anterior reconstruction. International Journal of Urology. 32(4). 355–360. 1 indexed citations
6.
Yamagishi, Atsushi, et al.. (2024). Herpes zoster development in living kidney transplant recipients receiving low‐dose rituximab. International Journal of Urology. 32(1). 88–93. 1 indexed citations
7.
Kita, Yuki, Katsuhiro Ito, Takuto Hara, et al.. (2024). Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. International Journal of Urology. 31(5). 552–559. 13 indexed citations
8.
Takeda, Yuji, Osamu Ichiyanagi, Shinichi Saitoh, et al.. (2023). Hemoglobin β Expression Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma. Biomedicines. 11(5). 1330–1330. 5 indexed citations
9.
Ito, Hiromi, et al.. (2023). Anti‐human leukocyte antigen and anti‐ABO antibodies after SARS‐CoV‐2 mRNA vaccination in kidney transplant recipients. Clinical Transplantation. 37(5). e14952–e14952. 2 indexed citations
10.
Yamagishi, Atsushi, et al.. (2022). Outcomes of Living Kidney Transplantation for Mitochondrial Disease Patients: A Case Series. Transplantation Proceedings. 54(2). 267–271. 3 indexed citations
11.
Ito, Hiromi, Atsushi Yamagishi, Toshihiko Sakurai, et al.. (2022). Immunogenicity and safety of two doses of SARS‐CoV‐2 mRNA vaccine in kidney transplant recipients with low‐dose rituximab. International Journal of Urology. 29(11). 1279–1286. 6 indexed citations
12.
Kato, Renpei, Sei Naito, Kazuyuki Numakura, et al.. (2022). Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study. International Journal of Clinical Oncology. 27(3). 563–573. 8 indexed citations
13.
Yamagishi, Atsushi, et al.. (2022). Changes in Visceral and Subcutaneous Adipose Tissue and Body Composition in Kidney Transplant Recipients at 1, 3, and 5 Years After Kidney Transplant. Transplantation Proceedings. 54(2). 351–354. 1 indexed citations
14.
Yamagishi, Atsushi, Toshihiko Sakurai, Sei Naito, et al.. (2021). Adjuvant heparinization before manipulation of artery reduces early failure in primary arteriovenous fistula for end-stage renal disease patients. Clinical and Experimental Nephrology. 25(12). 1346–1353. 1 indexed citations
15.
Yamagishi, Atsushi, Osamu Ichiyanagi, Toshihiko Sakurai, et al.. (2020). Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin‐induced thrombocytopenia. SHILAP Revista de lepidopterología. 3(3). 86–89. 2 indexed citations
16.
Naito, Sei, et al.. (2012). Continuous Transilience Induced Blindness - H-V Anisotropy and Luminance Asymmetry of disappearance -. Journal of Vision. 12(9). 890–890. 1 indexed citations
17.
Naito, Sei, et al.. (2012). Continuous Transilience Induced Blindness -Annulus, Sectors, and near fovea elements disappearance-. Journal of Vision. 12(9). 892–892. 1 indexed citations
18.
Akaza, Hideyuki, Tadashi Tsukamoto, Tomoaki Fujioka, et al.. (2011). Combined Immunotherapy with Low-dose IL-2 Plus IFN-  for Metastatic Renal Cell Carcinoma: Survival Benefit for Selected Patients with Lung Metastasis and Serum Sodium Level. Japanese Journal of Clinical Oncology. 41(8). 1023–1030. 14 indexed citations
19.
Naito, Sei, Vladimir Bilim, Kaori Yuuki, et al.. (2010). Glycogen Synthase Kinase-3β: A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer. Clinical Cancer Research. 16(21). 5124–5132. 72 indexed citations
20.
Naito, Sei, et al.. (1989). [Urothelial carcinoma related to exposure to aromatic amines].. PubMed. 35(12). 2023–31.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026